Abstract
In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon α (given subcutaneously 3 MU day–1, thrice weekly), for patients with primary melanomas of at least 3 mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon-α resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (P< 0.05). However, at a median follow-up of over 6 years, although there was an apparent improvement in disease-free survival (from 9 to 22 months), and overall survival (from 27 to 39 months), consistent with larger studies powered to detect such differences, these differences were not statistically significant. The data therefore suggest that 6 months of low-dose interferon is active, and confirm the importance of the large randomized studies, such as the UKCCCR AIM-High and EORTC trials, that seek to confirm a possible survival advantage for low or intermediate dose interferon. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cascinelli N (1995) Evaluation of efficacy of adjuvant rlFN alpha 2a in melanoma patients with regional node metastases (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 14: A1296
Cascinelli N (1999). Data presented at 3rd International Conference on Adjuvant Therapy of Malignant Melanoma, London
Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet SL, Chastang C and Bonerandi JJ (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Co-operative Group on Melanoma. [see comments]. Lancet 351: 1905–1910
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH (1996) Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17
Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M and Blum RH (2000a) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444–2458
Kirkwood JM, Ibrahim J, Sondak VK, Sosman JA and Ernstoff MS (2000b) Relapse-free and overall survival are significantly prolonged by high-dose IFN alpha 2b (HDI) compared to vaccine GM2-KLH with QS21 (GMK, Progenics) for high-risk resected stage IIB-III melanoma: Results of the Intergroup Phase III study E1694/S9512/C503801. Eur J Cancer 11 (Supp 4),
Legha SS (1986) Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer 57: 1675–1677
Mackie R, Hunter JA, Aitchison TC, Hole D, Mclaren K, Rankin R, Blessing K, Evans AT, Hutcheon AW and Jones DH (1992) Cutaneous malignant melanoma, Scotland, 1979–89. The Scottish Melanoma Group. Lancet 339: 971–975
Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auböck J, Fritsch P, Kerl H and Wolff K (1998) Adjuvant interferon Alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16: 1425–1429
Rusciani L, Petraglia S, Alotto M, Calvieri S and Vezzoni G (1997) Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 79: 2354–2360
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cameron, D., Cornbleet, M., Mackie, R. et al. Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study. Br J Cancer 84, 1146–1149 (2001). https://doi.org/10.1054/bjoc.2000.1623
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1623
Keywords
This article is cited by
-
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
BMC Cancer (2021)
-
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
Cancer Immunology, Immunotherapy (2019)
-
Adjuvant Therapy for Melanoma
Current Oncology Reports (2017)